Competitive Technologies Inc. announced that is has negotiated a five-year extension to its agreement for the Calmare pain therapy device utilizing 'Scrambler Therapy' technology. The agreement provided a five-year term expiring March 30, 2016 which has now been extended to March 30, 2021. In a related decision, CTTC has chosen to concentrate its sales and marketing programs for the Calmare device primarily in the Western Hemisphere including the USA, Canada, Mexico and the countries of Central and South America, as well as Australia and New Zealand. As opportunities arise for Calmare-related sales or distribution activities in countries outside the focus region, CTTC will coordinate with Professor Marineo who will be managing such activities for the mutual benefit of the partners.